Glaucoma Clinical Trial
Official title:
The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.
Status | Completed |
Enrollment | 25 |
Est. completion date | November 2011 |
Est. primary completion date | October 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Ability to provide written informed consent and comply with study assessments for the full duration of the study - Age > 18 years - Ischemic CRVO within 3 months of enrollment as per the following inclusion criteria - Three of the following clinical tests must be present to demonstrate ischemic CRVO: - VA 20/200 or worse - RAPD 0.9 LU or worse - Loss of 1-2e isopter on Goldmann Visual field (Kwon et al. 2001) - ERG demonstrating b wave amplitude less than 60% of A wave Exclusion Criteria: - Angle neovascularization greater than 3 clock hours with IOP over 30 (Neovascular glaucoma) - Any previous retinal laser photocoagulation to the study eye - Any previous intravitreal injection in study eye (triamcinolone or other) - Any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery) - Intracapsular cataract extraction (posterior capsule needs to be present) - Previous history of retinal detachment in study eye - Any previous radiation treatments to head/ neck - Inability to assess iris neovascularization (corneal opacity precluding gonioscopy) - Significant cardiovascular disease or cancer that would prevent follow-up visits or completion of the 12 month study - Significant diabetic retinopathy in the fellow eye (diabetic macular edema, proliferative diabetic retinopathy, or high-risk non-proliferative diabetic retinopathy) - Pregnancy (positive pregnancy test) - Prior enrollment in any study for vein occlusion in the study eye - Participation in another simultaneous medical investigator or trial - Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., DME AMD, ocular histoplasmosis, or pathologic myopia) - Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period - Aphakia or absence of the posterior capsule in the study eye - Previous violation of the posterior capsule is also excluded unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation. - History of idiopathic or autoimmune uveitis in either eye - Structural damage to the center of the macula in the study eye preexisting to CRVO likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s) - Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by OCT - Ocular inflammation (including trace or above) in the study eye - Uncontrolled glaucoma (defined as intraocular pressure =30 mm Hg despite treatment with anti- medications) or previous filtration surgery in the study eye - Systemic Conditions - Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during the screening period - Uncontrolled diabetes mellitus - Renal failure requiring dialysis or renal transplant - Premenopausal women not using adequate contraception - Previous participation in other studies of investigational drugs (excluding vitamins and minerals) within 3 months preceding Day 0 - History of other disease, metabolic dysfunction, physical examination finding, or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Instituto de Olhos de Goiania |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraocular Bevacizumab (Avastin) for Rubeosis Iridis | RI was investigated prospectively by iris biomicroscopy. An expanded informed consent with an off-label use waiver and explanation letter was reviewed with all patients | Compare results | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A |